BCD-248

· Biocad

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BCD-248, covering 2025-02-04 to 2025-02-04. Get the full timeline:

Most recent: Clinical Trial Update: An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]

See pricing